NasdaqGS:AARDPharmaceuticals
A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves
Aardvark Therapeutics (AARD) has put its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome on hold after reversible cardiac issues at higher doses, triggering delays, legal scrutiny, and sharp share price swings.
See our latest analysis for Aardvark Therapeutics.
The HERO trial pause has been the clear driver of volatility, with Aardvark Therapeutics’ 1-day share price return of 15.1% coming after sharp declines, including a 57.6% 30-day share price loss and a 50.4% 1-year total...